NCT00004786View on ClinicalTrials.gov

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

PHASE3CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

December 31, 1995

Conditions

Systemic SclerosisRaynaud Disease

Interventions

DRUG

iloprost

All Listed Sponsors

collaborator

University of Pittsburgh

OTHER

lead

National Center for Research Resources (NCRR)

NIH